var data={"title":"Meropenem: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Meropenem: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6538?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=meropenem-patient-drug-information\" class=\"drug drug_patient\">see &quot;Meropenem: Patient drug information&quot;</a> and <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Meropenem: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193322\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Merrem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193323\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Meropenem For Injection;</li>\n      <li>Merrem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193364\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Carbapenem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193326\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> IV: 1.5 to 6 g daily divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended infusion method </i>(off-label dosing): IV: 0.5 to 2 g over 3 hours every 8 hours (Crandon 2011; Dandekar 2003). <b>Note:</b> Dosing used at some centers and is based on pharmacokinetic/pharmacodynamic modeling and not clinical efficacy data. Meropenem stability (admixed with NS at a concentration of 20 mg/mL) at room temperature for &gt;1 hour or under refrigeration for &gt;15 hours is not supported by the manufacturer. Data exist supporting stability (admixed with NS at a concentration of 20 mg/mL) at room temperature for &le;4 hours and under refrigeration &le;24 hours (Patel 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Bacterial meningitis (off-label use): </b>IV: 2 g every 8 hours; duration of therapy dependent upon pathogen: <i>N. meningitidis</i>, <i>H. influenza</i>: 7 days; <i>S. pneumoniae</i>: 10 to 14 days; <i>Listeria monocytogenes, </i>aerobic gram-negative bacilli: 21 days (IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter-related bloodstream infections (off-label use):</b> IV: 1 g every 8 hours (Mermel 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cholangitis, intra-abdominal infections, complicated:</b> IV: 1 g every 8 hours. <b>Note:</b> 2010 IDSA guidelines recommend treatment duration of 4 to 7 days (provided source controlled). Not recommended for mild-to-moderate, community-acquired intra-abdominal infections due to risk of toxicity and the development of resistant organisms (Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pulmonary exacerbation (off-label use):</b> IV: 2 g every 8 hours (Chmiel 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Febrile neutropenia (off-label use):</b> IV: 1 g every 8 hours (Ohata 2011; Paul 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gynecologic and pelvic infections (off-label use): </b> IV: 500 mg every 8 hours (Hemsell 1997; Maggioni 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Melioidosis <i>(Burkholderia pseudomallei)</i> (off-label use):</b> IV: Initial treatment (intensive-phase): 1 g every 8 hours (Cheng 2004; Inglis 2006; Lipsitz 2012). <b>Note:</b> Meropenem is an alternative treatment to ceftazidime for melioidosis; continued treatment with oral antibiotics is recommended after intensive-phase is completed (Lipsitz 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia (hospital-acquired, healthcare-associated, or ventilator-associated) (off-label use):</b> IV: 1 g every 8 hours (ATS/IDSA 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prosthetic joint infection, <i>Pseudomonas aeruginosa</i> (off-label use):</b> IV: 1 g every 8 hours for 4 to 6 weeks (consider addition of aminoglycoside) (IDSA [Osmon 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections, complicated: </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pseudomonas aeruginosa</i>-suspected or confirmed: 1 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pseudomonas aeruginosa</i> not suspected: 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> IV: 1 g every 8 hours in combination with an agent effective against MRSA (eg, vancomycin, linezolid, daptomycin) for empiric therapy of polymicrobial (mixed) infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical site infection (intestinal or genitourinary tract surgery) (off-label use):</b> IV: 1 g every 8 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections, complicated (off-label use):</b> IV: 500 mg to 1 g every 8 hours (Pallett 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193345\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Meropenem: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &lt;3 months: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gestational age &lt;32 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postnatal age &lt;14 days: 20 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postnatal age &ge;14 days: 20 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gestational age &ge;32 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postnatal age &lt;14 days: 20 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postnatal age &ge;14 days: 30 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;3 months, Children, and Adolescents (&le;50 kg): IV: 30 to 120 mg/kg/day divided every 8 hours (maximum dose: 6 <b>g</b> daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (&gt;50 kg): IV: 1.5 to 6 g daily divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter-related blood stream infections (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents (&le;50 kg): IV: 20 mg/kg every 8 hours; maximum single dose: 1,000 mg (Mermel 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (&gt;50 kg): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cholangitis, intra-abdominal infections, complicated:</b> IV: Children and Adolescents (&gt;50 kg): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pulmonary exacerbation (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents (&le;50 kg): 40 mg/kg every 8 hours; maximum single dose: 2,000 mg (Zobell 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (&gt;50 kg): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Febrile neutropenia (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents (&le;50 kg): 20 mg/kg every 8 hours (maximum dose: 1,000 mg every 8 hours) (Lehrnbecher 2012; Yildirim 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (&gt;50 kg): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infections (complicated):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;3 months: IV: <b>Note:</b> Administer as an IV infusion over 30 minutes; do not administer as an IV bolus</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gestational age &lt;32 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Postnatal age &lt;14 days: 20 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Postnatal age &ge;14 days: 20 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gestational age &ge;32 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Postnatal age &lt;14 days: 20 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Postnatal age &ge;14 days: 30 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents: 20 mg/kg every 8 hours (maximum dose: 1,000 mg every 8 hours) for 4 to 7 days (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Melioidosis <i>(Burkholderia pseudomallei)</i> (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months, Children, and Adolescents (&le;40 kg): Initial treatment (intensive-phase): 25 mg/kg (up to 1 g) every 8 hours (Cheng 2004). <b>Note: </b> Meropenem is an alternative treatment to ceftazidime for melioidosis; continued treatment with oral antibiotics is recommended after intensive-phase is completed (Lipsitz 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (&gt;50 kg): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents (&le;50 kg): 40 mg/kg every 8 hours (maximum dose: 2,000 mg every 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (&gt;50 kg): 2 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prosthetic joint infection, </b>\n      <b>\n        <i>Pseudomonas aeruginosa</i></b> <b>(off-label use):</b> Children and Adolescents (&gt;50 kg): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents (&le;50 kg):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Complicated:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Pseudomonas aeruginosa</i>-suspected or confirmed: 20 mg/kg every 8 hours (maximum dose: 1,000 mg every 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Pseudomonas aeruginosa</i> not suspected: 10 mg/kg every 8 hours (maximum dose: 500 mg every 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (&gt;50 kg): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> IV: 20 mg/kg every 8 hours in combination with an agent effective against MRSA (eg, vancomycin, linezolid, daptomycin) for empiric therapy of polymicrobial (mixed) infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection (complicated):</b> IV: Children and Adolescents (&gt;50 kg): Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193327\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193328\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 26 to 50 mL/minute: Administer recommended dose based on indication every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 25 mL/minute: Administer one-half recommended dose based on indication every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Administer one-half recommended dose based on indication every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations: </i>\n      <b>Note:</b> Renally adjusted dose recommendations are based on doses of 1 to 2 g every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 50 mL/minute: Administer recommended dose based on indication every 12 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute: Administer recommended dose based on indication every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Meropenem and its metabolite are readily dialyzable: 500 mg every 24 hours (Heintz, 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (off-label dose): Administer recommended dose (based on indication) every 24 hours (Aronoff, 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Kuti 2005; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH: Consider loading dose of 1 g followed by either 500 mg every 8 hours <b>or</b> 1 g every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHD/CVVHDF: Consider loading dose of 1 g followed by either 500 mg every 6 to 8 hours <b>or</b> 1 g every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Consider giving patients receiving CVVHDF dosages of 750 mg every 8 hours <b>or</b> 1.5 g every 12 hours (Heintz, 2009). Substantial variability exists in various published recommendations, ranging from 1 to 3 g daily in 2 to 3 divided doses. One gram every 12 hours achieves a target trough of ~4 mg/L.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations </i>(off-label dosing; Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute: Administer 20 to 40 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute: Administer 10 to 20 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute: Administer 10 to 20 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD): 10 to 20 mg/kg every 24 hours administer after hemodialysis on dialysis days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): 10 to 20 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT): 20 to 40 mg/kg every 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570370\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193298\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Merrem: 500 mg (1 ea); 1 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1 g (1 ea); 1 g/50 mL in NaCl 0.9% (1 ea); 500 mg/50 mL in NaCl 0.9% (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193283\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193302\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &lt;3 months: Administer as an IV infusion over 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &ge;3 months, Children, Adolescents, and Adults: Administer IV infusion over 15 to 30 minutes; IV bolus injection (5 to 20 mL) over 3 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended infusion administration (off-label dosing): Adults: Administer over 3 hours (Crandon 2011; Dandekar, 2003). <b>Note:</b> Must consider meropenem&rsquo;s limited room temperature stability if using extended infusions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193301\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial meningitis:</b> Treatment of bacterial meningitis in pediatric patients 3 months and older caused by <i>Haemophilus influenzae</i>, <i>Neisseria meningitidis</i>, and penicillin-susceptible isolates of <i>Streptococcus pneumoniae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections, complicated:</b> Treatment of complicated skin and skin structure infections in adults and pediatric patients 3 months and older caused by <i>Staphylococcus aureus</i> (methicillin-susceptible isolates only), <i>Streptococcus pyogenes</i>, <i>Streptococcus</i><i> agalactiae</i>, viridans group streptococci, <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates only), <i>Pseudomonas aeruginosa</i>, <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Bacteroides fragilis</i>, and <i>Peptostreptococcus</i> species.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections:</b> Treatment of complicated appendicitis and peritonitis in adult and pediatric patients caused by viridans group streptococci, <i>E. coli</i>, <i>Klebsiella pneumoniae</i>, <i>P. aeruginosa</i>, <i>B. fragilis</i>, <i>B. thetaiotaomicron</i>, and <i>Peptostreptococcus</i> species.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25572938\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bacterital meningitis; Catheter-related blood stream infections; Cystic fibrosis, pulmonary exacerbation; Febrile neutropenia; Gynecologic and pelvis infection; Melioidosis (Burkholderia pseudomallei); Pneumonia, hospital-acquired or ventilator-associated; Prosthetic joint infection; Skin and soft tissue necrotizing infections; Surgical site Infection; Urinary tract infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027563\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Meropenem may be confused with ertapenem, imipenem, metroNIDAZOLE</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193290\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral vascular disease (&gt;1%), shock (1%), bradycardia (&le;1%), cardiac arrest (&le;1%), cardiac failure (&le;1%), chest pain (&le;1%), hypertension (&le;1%), hypotension (&le;1%), myocardial infarction (&le;1%), peripheral edema (&le;1%), pulmonary embolism (&le;1%), syncope (&le;1%), tachycardia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2% to 8%), convulsions (neonates and infants &lt;3 months: 5%), pain (&le;5%), agitation (&le;1%), anxiety (&le;1%), chills (&le;1%), confusion (&le;1%), delirium (&le;1%), depression (&le;1%), dizziness (&le;1%), drowsiness (&le;1%), hallucination (&le;1%), insomnia (&le;1%), nervousness (&le;1%), paresthesia (&le;1%), seizure (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (2% to 3%, includes diaper-area moniliasis in infants), pruritus (1%), dermal ulcer (&le;1%), diaphoresis (&le;1%), urticaria (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia (&gt;1%), hypervolemia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;8%), diarrhea (4% to 7%), constipation (1% to 7%), vomiting (&le;4%), oral candidiasis (&le;2%), gastrointestinal disease (&gt;1%), glossitis (1%), abdominal pain (&le;1%), anorexia (&le;1%), dyspepsia (&le;1%), enlargement of abdomen (&le;1%), flatulence (&le;1%), intestinal obstruction (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria (&le;1%), pelvic pain (&le;1%), urinary incontinence (&le;1%), vulvovaginal candidiasis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (&le;6%), hypochromic anemia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (conjugated; neonates and infants &lt;3 months: 5%), cholestatic jaundice (&le;1%), hepatic failure (&le;1%), jaundice (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Inflammation at injection site (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (&le;1%), weakness (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (&gt;1%), pneumonia (&gt;1%), apnea (1%), asthma (&le;1%), cough (&le;1%), dyspnea (&le;1%), hypoxia (&le;1%), pleural effusion (&le;1%), pulmonary edema (&le;1%), respiratory tract disease (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (&gt;1%), fever (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, angioedema, anorexia, asthma, bradycardia, change in platelet count, cholestatic jaundice, <i>Clostridium difficile</i> associated diarrhea, confusion, decreased hematocrit, decreased hemoglobin, decreased partial thromboplastin time, decreased prothrombin time, decreased white blood cell count, delirium, depression, dermal ulcer, DRESS syndrome, eosinophilia, erythema multiforme, gastrointestinal hemorrhage, hallucination, hematuria, hemolytic anemia, hemoperitoneum, hepatic failure, hypertension, hypervolemia, hypochromic anemia, hypokalemia, hypotension, hypoxia, increased blood urea nitrogen, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, ileus, intestinal obstruction, jaundice, leukocytosis, leukopenia, myocardial infarction, neutropenia, peripheral edema, pleural effusion, positive direct Coombs test, positive indirect Coombs test, pulmonary edema, pulmonary embolism, renal failure, seizure, Stevens-Johnson syndrome, tachycardia, toxic epidermal necrolysis, urinary incontinence, vulvovaginal candidiasis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193305\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to meropenem, other drugs in the same class, or any component of the formulation; patients who have experienced anaphylactic reactions to beta-lactams</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193287\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported (some without a history of previous allergic reactions to beta-lactams).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk. Outpatient use may result in paresthesias, seizures, delirium and/or headaches that can impair neuromotor function and alertness; patients should not operate machinery or drive until it is established that meropenem is well tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with creatinine clearance &le;50 mL/minute. Increased seizure risk and thrombocytopenia have been reported in patients with renal  impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions.  Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy.  Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Lower doses (based upon renal function) are often required in the elderly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299674\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193292\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9613&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Meropenem.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193294\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193307\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Incomplete transplacental transfer of meropenem was found using an <i>ex vivo</i> human perfusion model. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3878811\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Small amounts of meropenem are excreted into breast milk (case report). The manufacturer recommends that caution be exercised when administering meropenem to breastfeeding women. Nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193309\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193296\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Perform culture and sensitivity testing prior to initiating therapy. Monitor for signs of anaphylaxis during first dose. During prolonged therapy, monitor renal function, liver function, CBC. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193286\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to several of the penicillin-binding proteins, which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis; bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193304\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Penetrates into most tissues and body fluids including urinary tract, peritoneal fluid, bone, bile, lung, bronchial mucosa, muscle tissue, heart valves (Craig 1997), and CSF (CSF penetration: Neonates and Infants &le;3 months: 70%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates and Infants &le;3 months: Median: ~0.47 L/kg (Smith 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children: 0.3 to 0.4 L/kg (Blumer 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 15 to 20 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~2%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; hydrolysis of beta-lactam bond to open beta-lactam form (inactive) (Craig 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates and Infants &le;3 months: Median: 2.7 hours; range: 1.6 to 3.8 hours (Smith 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 3 months to 2 years: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to 12 years and Adults: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Tissue: ~1 hour following infusion except in bile, lung, and muscle; CSF: 2 to 3 hours with inflamed meninges</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~70% as unchanged drug; ~28% inactive metabolite); feces (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates and Infants &le;3 months: 0.12 L/hour/kg (Smith 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children: 0.26 to 0.37 L/hour/kg (Blumer 1995)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422265\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Meropenem Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Meropenem-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (1): $26.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/50 mL (1): $19.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Merrem Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $80.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $40.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193310\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Archifar (HR, MT, SG);</li>\n      <li>Bironem (VN);</li>\n      <li>Come (UA);</li>\n      <li>Elpenem (LK);</li>\n      <li>Enem (TH);</li>\n      <li>Eradix (ID);</li>\n      <li>Grambiot (PY);</li>\n      <li>Haizheng Meite (CN);</li>\n      <li>Lanmer (ID);</li>\n      <li>Mabapenem (KR);</li>\n      <li>Madiba (EC);</li>\n      <li>Mapenem (TH);</li>\n      <li>Mecapem (KR);</li>\n      <li>Meflupin (TW);</li>\n      <li>Melopen (TW);</li>\n      <li>Menem IV (PH);</li>\n      <li>Mepem (CN, TW);</li>\n      <li>Mepenan (UA);</li>\n      <li>Mero (TH);</li>\n      <li>Merobac I.V. (CO);</li>\n      <li>Merofen (ID);</li>\n      <li>Merogram (TZ);</li>\n      <li>Meromax (PH);</li>\n      <li>Meronem (AE, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CR, CU, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IS, JM, JO, KE, KW, LB, LR, LT, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NO, PA, PE, PH, PK, PL, PR, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, TH, TN, TR, TT, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Meronia (TZ);</li>\n      <li>Merop (PH);</li>\n      <li>Meropemed (PE);</li>\n      <li>Meropen (JP, KR, LK, PH);</li>\n      <li>Meropevex (PH);</li>\n      <li>Meroponia (IE);</li>\n      <li>Merosan (ID);</li>\n      <li>Merosayz (UA);</li>\n      <li>Merovex (PH);</li>\n      <li>Meroxi (ID);</li>\n      <li>Merozan (PH);</li>\n      <li>Merozen (PY);</li>\n      <li>Merrem (BB, IT, MX, NZ);</li>\n      <li>Monem (LK, MY, TH);</li>\n      <li>Myron (TW);</li>\n      <li>Nemmed (TH);</li>\n      <li>Newropenem (KR);</li>\n      <li>Opimer (ID);</li>\n      <li>Optinem (AT);</li>\n      <li>Penem (ID);</li>\n      <li>Penomer (LK);</li>\n      <li>Pisapem (EC);</li>\n      <li>Pospenem (KR);</li>\n      <li>Romenem (TH);</li>\n      <li>Ronem (ID);</li>\n      <li>Ropen (PH);</li>\n      <li>Tripenem (ID, MY, PH);</li>\n      <li>Zakster (UA);</li>\n      <li>Zaxter (TH);</li>\n      <li>Zeropenem (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 61, 153.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baldwin CM, Lyseng-Williamson KA, and Keam SJ, &ldquo;Meropenem: A Review of Its Use in the Treatment of Serious Bacterial Infections,&rdquo; <i>Drugs</i>, 2008, 68(6):803-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/18416587/pubmed\" target=\"_blank\" id=\"18416587\">18416587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, Reed MD, Kearns GL, et al, &ldquo;Sequential, Single-Dose Pharmacokinetic Evaluation of Meropenem in Hospitalized Infants and Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(8):1721-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/7486908/pubmed\" target=\"_blank\" id=\"7486908\">7486908</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16236892\"></a>Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. <i>Chest</i>. 2005;128(4):2336-2346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/16236892/pubmed\" target=\"_blank\" id=\"16236892\">16236892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley, JS, &ldquo;Meropenem: A New, Extremely Broad Spectrum Beta-lactam Antibiotic for Serious Infections in Pediatrics,&rdquo; <i>Pediatr Infect Dis J</i>, 1997, 16:263-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/9076812/pubmed\" target=\"_blank\" id=\"9076812\">9076812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8543489\"></a>Byrne S, Maddison J, Connor P, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. <i>J Antimicrob Chemother</i>. 1995;36 Suppl A:135-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/8543489/pubmed\" target=\"_blank\" id=\"8543489\">8543489</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15105132\"></a>Cheng AC, Fisher DA, Anstey NM, et al, &ldquo;Outcomes of patients with melioidosis treated with meropenem,&rdquo; <i>Antimicrob Agents Chemother</i>, 2004, 48(5):1763-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/15105132/pubmed\" target=\"_blank\" id=\"15105132\">15105132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25102221\"></a>Chmiel JF, Aksamit TR, Chotirmall SH, et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. <i>Ann Am Thorac Soc</i>. 2014;11(7):1120-1129.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/25102221/pubmed\" target=\"_blank\" id=\"25102221\">25102221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7578765\"></a>Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. <i>Clin Infect Dis</i>. 1995;21(1):86-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/7578765/pubmed\" target=\"_blank\" id=\"7578765\">7578765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Craig WA, &ldquo;The Pharmacology of Meropenem, a New Carbapenem Antibiotic,&rdquo; <i>Clin Infect Dis</i>, 1997, 24(Suppl 2):266-75.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crandon JL, Ariano RE, Zelenitsky SA, et al, &ldquo;Optimization of Meropenem Dosage in the Critically Ill Population Based on Renal Function,&rdquo; <i>Intensive Care Med</i>, 2011, 37(4):632-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/21136037/pubmed\" target=\"_blank\" id=\"21136037\">21136037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dandekar PK, Maglio D, Sutherland CA, et al, &ldquo;Pharmacokinetics of Meropenem 0.5 and 2 g Every 8 Hours as a 3-Hour Infusion,&quot; <i>Pharmacotherapy</i> 2003, 23(8):988-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/12921245/pubmed\" target=\"_blank\" id=\"12921245\">12921245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fish DN and Singletary TJ, &ldquo;Meropenem, A New Carbapenem Antibiotic,&rdquo; <i>Pharmacotherapy</i>, 1997, 17(4):644-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/9250544/pubmed\" target=\"_blank\" id=\"9250544\">9250544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21258094\"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/21258094/pubmed\" target=\"_blank\" id=\"21258094\">21258094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10221472\"></a>Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. <i>Mayo Clin Proc</i>. 1999;74(4):420-434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/10221472/pubmed\" target=\"_blank\" id=\"10221472\">10221472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9126697\"></a>Hemsell DL, Martens MG, Faro S, Gall S, McGregor JA. A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. <i>Clin Infect Dis</i>. 1997;24(Suppl 2):S222-230.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/9126697/pubmed\" target=\"_blank\" id=\"9126697\">9126697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inglis TJJ, Rolim DB, Rodriguez JLN, &ldquo;Clinical guideline for diagnosis and management of melioidosis,&rdquo; <i>Rev Inst Med Trop S. Paulo</i>, 2006, 48(1):1-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/16547571/pubmed\" target=\"_blank\" id=\"16547571\">16547571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krueger WA, Schroeder TH, Hutchison M, et al, &ldquo;Pharmacokinetics of Meropenem in Critically Ill Patients With Acute Renal Failure Treated by Continuous Hemodiafiltration,&rdquo; <i>Antimicrob Agents Chemother</i>, 1998, 42(9):2421-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/9736574/pubmed\" target=\"_blank\" id=\"9736574\">9736574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15985760\"></a>Kuti JL, Nicolau DP. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. <i>Chemotherapy</i>. 2005;51(4):211-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/15985760/pubmed\" target=\"_blank\" id=\"15985760\">15985760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17766190\"></a>Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. <i>J Cyst Fibros</i>. 2008;7(2):142-146<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/17766190/pubmed\" target=\"_blank\" id=\"17766190\">17766190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehrnbecher T, Phillips R, Alexander S, et al, &ldquo;Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoetic stem-cell transplantation,&rdquo; <i>J Clin Oncol</i>, 2012, 30(35):4427-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/22987086/pubmed\" target=\"_blank\" id=\"22987086\">22987086</a>]</span><span class=\"doi\">10.1200/JCO.2012.42.7161</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linden P, &ldquo;Safety Profile of Meropenem: An Updated Review of Over 6,000 Patients Treated With Meropenem,&rdquo; <i>Drug Saf</i>, 2007, 30(8):657-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/17696578/pubmed\" target=\"_blank\" id=\"17696578\">17696578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23171644\"></a>Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. <i>Emerg Infect Dis</i>. 2012;18(12):e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/23171644/pubmed\" target=\"_blank\" id=\"23171644\">23171644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ljungberg B and Nilsson-Ehle I, &ldquo;Pharmacokinetics of Meropenem an Its Metabolites in Young and Elderly Healthy Men,&rdquo; <i>Antimicrob Agents Chemother</i>, 1992, 36(7):1437-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/1510440/pubmed\" target=\"_blank\" id=\"1510440\">1510440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9603636\"></a>Maggioni P, Di Stefano F, Facchini V, et al. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin. <i>J Chemother</i>. 1998;10(2):114-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/9603636/pubmed\" target=\"_blank\" id=\"9603636\">9603636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44(suppl 2):S27-S72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al, &ldquo;Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America,&rdquo; <i>Clin Inf Dis</i>, 2009, 49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span><span class=\"doi\">10.1086/599376</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meropenem for injection and sodium chloride injection [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merrem (meropenem) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merrem (meropenem) [product monograph], Mississauga, Ontario, Canada: AstraZeneca Canada Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolau DP, &ldquo;Pharmacodynamic Optimization of Beta-lactams in the Patient Care Setting,&rdquo; <i>Critical Care</i>, 2008, 12(Suppl 4):2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/18495059/pubmed\" target=\"_blank\" id=\"18495059\">18495059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohata Y, Tomita Y, Nakayama M, et al, &ldquo;Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis,&rdquo; J Infect Chemother, 2011, 17(6):831-841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/21773752/pubmed\" target=\"_blank\" id=\"21773752\">21773752</a>]</span><span class=\"doi\">10.1007/s10156-011-0271-9</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20876625\"></a>Pallett A and Hand K, &ldquo;Complicated Urinary Tract Infections: Practical Solutions for the Treatment of Multiresistant Gram-Negative Bacteria,&rdquo; <i>J Antimicrob Chemother</i>, 2010, 65(Suppl 3):25-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/20876625/pubmed\" target=\"_blank\" id=\"20876625\">20876625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel PR, Cook SE, &ldquo;Stability of meropenem in intravenous solutions,&rdquo; <i>Am J Health-Syst Pharm</i>, 1997, 54(4):412-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/9043564/pubmed\" target=\"_blank\" id=\"9043564\">9043564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paul M, Yahav D, Bivas A, et al, &ldquo;Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams,&rdquo; <i>Cochrane Database Syst Rev</i>, 2010, (11):CD005197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/21069685/pubmed\" target=\"_blank\" id=\"21069685\">21069685</a>]</span><span class=\"doi\">10.1002/14651858.CD005197.pub3</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith PB, Cohen-Wolkowiez M, Castro LM, et al, &ldquo;Population Pharmacokinetics of Meropenem in Plasma and Cerebrospinal Fluid of Infants With Suspected or Complicated Intra-abdominal Infections,&quot;<i>Pediatr Infect Dis J</i>, 2011, 30(10):844-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/21829139/pubmed\" target=\"_blank\" id=\"21829139\">21829139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ververs TF, van Dijk A, Vinks SA, et al, &ldquo;Pharmacokinetics and Dosing Regimen of Meropenem in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration,&rdquo; <i>Crit Care Med</i>, 2000, 28(10):3412-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/11057794/pubmed\" target=\"_blank\" id=\"11057794\">11057794</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiseman LR, Wagstaff AJ, Brogden RN, et al, &ldquo;Meropenem. A Review of its Antibacterial Activity, Pharmacokinetic Properties and Clinical Efficacy,&rdquo; <i>Drugs</i>, 1995, 50(1):73-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/7588092/pubmed\" target=\"_blank\" id=\"7588092\">7588092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yildirim I, Aytac S, Ceyhan M, et al, &quot;Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies,&quot; <i>Pediatr Hematol Oncol</i>, 2008, 25(4):291-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/18484473/pubmed\" target=\"_blank\" id=\"18484473\">18484473</a>]</span><span class=\"doi\">10.1080/08880010802016847</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22911974\"></a>Zobell JT, Young DC, Waters CD, et al, &quot;Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems,&quot; <i>Pediatr Pulmonol</i>, 2012, 47(12):1147-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-drug-information/abstract-text/22911974/pubmed\" target=\"_blank\" id=\"22911974\">22911974</a>]</span><span class=\"doi\">10.1002/ppul.22655</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9613 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F193322\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193323\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F193364\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F193326\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F193345\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F193327\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F193328\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16570370\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193298\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F193283\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F193302\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F193301\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25572938\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6027563\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193290\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193305\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193287\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299674\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F193292\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193294\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F193307\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3878811\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F193309\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F193296\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193286\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F193304\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422265\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193310\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9613|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=meropenem-patient-drug-information\" class=\"drug drug_patient\">Meropenem: Patient drug information</a></li><li><a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">Meropenem: Pediatric drug information</a></li></ul></div></div>","javascript":null}